Form SC 13G/A Aclaris Therapeutics, Filed by: CITADEL ADVISORS LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- Wall St set for muted open as tech stocks take a breather
- Stifel sees AI supply constraints ahead of Q3 tech earnings
- Schneider Electric to buy US software firm PTC in $22.6 billion deal
Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)
November 18, 2024 12:34 PM ESTStifel analyst Alex Thompson reiterated a Hold rating and $3.00 price target on Aclaris Therapeutis (NASDAQ: ACRS)
The analyst comments "Aclaris announced a licensing agreement with Biosion to acquire ex-China rights to a clinical stage TSLP mAb (BSI-045B) and a preclinical TSLPxIL-4R bispecific (BSI-502). The... More



